Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
| ▸ | TK1 | P04183 | 3/20 | 0.49 |
| ▸ | TK2 | O00142 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6852678 | 1.00 | LMNA (0.67) | LMNASMN1; SMN2RNASE1SLC6A2ALOX12 | |
| SCHEMBL13026818 | 1.00 | LMNA (0.67) | LMNASMN1; SMN2RNASE1SLC6A2ALOX12 | |
| SCHEMBL16311910 | 0.91 | LMNA (0.57) | LMNASMN1; SMN2RNASE1TK1TK2 | |
| SCHEMBL24595722 | 0.89 | LMNA (0.55) | LMNASMN1; SMN2RNASE1SLC6A2TK1 | |
| SCHEMBL570200 | 0.89 | LMNA (0.55) | LMNASMN1; SMN2RNASE1TK1 | |
| SCHEMBL8329362 | 0.89 | LMNA (0.55) | LMNASMN1; SMN2RNASE1TK1 | |
| SCHEMBL6075436 | 0.88 | RNASE1 (0.74) | LMNARNASE1TK1 | |
| SCHEMBL31289437 | 0.88 | RNASE1 (0.74) | LMNARNASE1TK1 | |
| SCHEMBL265601 | 0.88 | RNASE1 (0.74) | LMNARNASE1TK1 | |
| SCHEMBL265600 | 0.88 | RNASE1 (0.74) | LMNARNASE1TK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4816570-A | Biologically reversible phosphate and phosphonate protective groups | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 1989-03-28 | — | — | US | claimed |
| JP-59093096-A | — | — | None | — | — | JP | disclosed |
| US-8673885-B1 | Compounds for the protection of sulfur containing linkers in nucleic acid synthesis | DUFF ROBERT (US) | 2014-03-18 | — | — | US | disclosed |
| US-20050090659-A1 | Phospholepid derivatives of nucleosides as antitumaorl medicaments | GANYMED 256 VERMOEGENSVERWALTUNGS GMBH (DE) | 2005-04-28 | — | — | US | disclosed |
| US-6787525-B1 | METHOD OF TREATING HIV INFECTIONS AND/OR CANCER DISEASES | SCHOTT HERBERT (DE) | 2004-09-07 | — | — | US | disclosed |
| EP-0331032-B1 | 2'-DEOXY-5-FLUOROURIDINE DERIVATIVES | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1993-04-28 | — | — | EP | disclosed |
| US-5032680-A | Antitumor | KURARAY CO., LTD. (JP) | 1991-07-16 | — | — | US | disclosed |
| EP-0331032-A1 | 2'-Deoxy-5-fluorouridine derivatives | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1989-09-06 | — | — | EP | disclosed |
| US-4605645-A | ANTITUMOR AGENTS | TEIJIN LIMITED (JP) | 1986-08-12 | — | — | US | disclosed |
| EP-0081386-B1 | 5-FLUORO-2'-DEOXYURIDINE DERIVATIVES AND A PROCESS FOR THE PREPARATION THEREOF | TEIJIN LIMITED (JP) | 1985-05-29 | — | — | EP | disclosed |
| JP-S5993096-A | 5-FLUORO-2'-DEOXYURIDINE DERIVATIVE AND ITS PREPARATION | TEIJIN LTD | 1984-05-29 | — | — | JP | disclosed |
| EP-0081386-A1 | 5-Fluoro-2'-deoxyuridine derivatives and a process for the preparation thereof | TEIJIN LIMITED (JP) | 1983-06-15 | — | — | EP | disclosed |
| US-4056673-A | VIRICIDE, ANTINEOPLASTIC | HOFFMANN-LA ROCHE INC. (US) | 1977-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090659-A1 | Phospholepid derivatives of nucleosides as antitumaorl medicaments | PHOSPHO1, TYMP, PNP | LMNA 759/4885SMN1; SMN2 1063/4885RNASE1 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.